Newly Activated Clinical Trials

This is a listing of clinical trials recently activated by the University of Illinois Cancer Center Clinical Trials Office for patient enrollment. Click the study links below to learn details regarding the studies on clinicaltrials.gov. You can also search for other clinical trials on our website. For more information or questions about a study, email [email protected] or call 312-355-5112.

---

Protocol Title: COPERNICUS:  A Phase 2b, Open-Label, Two-Cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-Line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS)

Sponsors: Janssen Pharmaceutical, Inc., a company of Johnson & Johnson

Principal Investigator: Ryan Nguyen, DO

---